What is the IGX.TO share price today?

This page shows the latest available IntelGenx Technologies Corp. (IGX.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is IntelGenx Technologies Corp. listed?

IntelGenx Technologies Corp. trades on the Toronto Stock Exchange under the symbol IGX.TO, ISIN US45822R1014.

How large is IntelGenx Technologies Corp.?

Its market capitalisation is approximately 41.92M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · IGX.TO · ISIN US45822R1014

IntelGenx Technologies Corp.

No trading activity has been reported for this listing since May 16, 2024. It may be delisted, halted or inactive.

0.2400 CAD

May 16, 2024

IntelGenx Technologies Corp. (IGX.TO) trades on the Toronto Stock Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 41.92M CAD. Its ISIN is US45822R1014. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

US45822R1014

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

41.92M CAD

Previous close

0.20 CAD

Day range

0.21 – 0.24

52-week range

0.14 – 0.30

Volume

50-day average

0.23 CAD

200-day average

0.21 CAD

Asset type

Equity

About IntelGenx Technologies Corp.

IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.

Company website

Frequently asked

What is the IGX.TO share price today?: This page shows the latest available IntelGenx Technologies Corp. (IGX.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is IntelGenx Technologies Corp. listed?: IntelGenx Technologies Corp. trades on the Toronto Stock Exchange under the symbol IGX.TO, ISIN US45822R1014.
How large is IntelGenx Technologies Corp.?: Its market capitalisation is approximately 41.92M CAD, based on the latest available price and share count from our data provider.

All IntelGenx Technologies Corp. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.